Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma.

ABSTRACT:

Background

Checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, yielding long-term survival in a considerable proportion of the patients. Yet, 40-60% of patients do not achieve a long-term benefit from such therapy, emphasizing the urgent need to identify biomarkers that can predict response to immunotherapy and guide patients for the best possible treatment. Here, we exploited an unsupervised machine learning approach to identify potential inflammatory cytokine signatures from liquid biopsies, which could predict response to immunotherapy in melanoma.

Methods

We studied a cohort of 77 patients diagnosed with unresectable advanced-stage melanoma undergoing treatment with first-line nivolumab plus ipilimumab or pembrolizumab. Baseline and on-treatme

SUBMITTER: Pedersen JG 

PROVIDER: S-EPMC9322974 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature